A Study of the Effect of IW-1701 (Olinciguat), a Stimulator of Soluble Guanylate Cyclase (sGC), on Patients With Sickle Cell Disease (SCD) (STRONG SCD)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03285178 |
|
Recruitment Status :
Completed
First Posted : September 15, 2017
Last Update Posted : July 22, 2021
|
Sponsor:
Cyclerion Therapeutics
Information provided by (Responsible Party):
Cyclerion Therapeutics
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Completed |
|---|---|
| Actual Primary Completion Date : | July 22, 2020 |
| Actual Study Completion Date : | July 22, 2020 |
| Certification/Extension First Submitted : | July 18, 2021 |